Timothy A Yap, from the University of Texas MD Anderson Cancer Center, Houston, TX, US, discusses recent advances and challenges in precision cancer medicine, and how we can improve awareness and understanding of this important subject in the wider community.
1. What have been the most important advances in precision cancer medicine in the last year? (0:08)
2. What are the short- and long-term goals of precision medicine in oncology? (1:55)
3. How can we overcome the challenges of tumour heterogeneity and clonal evolution? (2:36)
4. How do you decide which trial to offer patients using precision medicine technologies? (3:46)
5. How can we improve public awareness and understanding of precision medicine? (4:41)
Speaker disclosures: Timothy A Yap has nothing to disclose in relation to this video interview.
Filmed at the American Association for Cancer Research (AACR) Annual Meeting 2018, Chicago, IL, US, April 14–18, 2018.
Share this Video
Related Videos In Prostate Cancer
Axel Merseburger, ASCO GU 2021: Apalutamide in Metastatic Castration-sensitive Prostate Cancer
We were delighted to talk to Editor-in-Chief Prof. Axel Merseburger (Professor and Chairman, Department of Urology, University of Lübeck, Lübeck, Germany) around the TITAN trial in metastatic castration-sensitive prostate cancer (ClinicalTrials.gov Identifer: NCT02489318). The abstract “Final analysis results from TITAN: A phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic […]
Julie Graff, ESMO 2019 – KEYNOTE-641 study in prostate cancer
We met with Julie Graff (Knight Cancer Institute) at ESMO 2019 to discuss unmet needs in the treatment of metastatic castration-resistant prostate cancer and KEYNOTE-641 (NCT03834493), a phase III study of pembrolizumab plus enzalutamide in this patient population. Questions 1. What are the current unmet needs in the treatment of metastatic castration-resistant prostate cancer (mCRPC) […]
Axel Merseburger, ESMO 2019 – Advances in metastatic hormone-sensitive prostate cancer
Our Editor-in-Chief, Axel Merseberger (University Hospital Schleswig-Holstein), joined us at ESMO 2019 to discuss current limitations in the treatment of metastatic hormone-sensitive prostate cancer, use of antiandrogen agents, and what the future may hold. Questions 1. What are the limitations of the current standard of care for metastatic hormone-sensitive prostate cancer (mHSPC)? (0:05) 2. […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!